GlassScriptPhysician profile
Jodi D Langer
NPI 1639325194
$10,897.50
in general payments reported to CMS, 2019-2025
30 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $227 · 2021: $1,261 · 2022: $1,881 · 2023: $1,506 · 2024: $2,301 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,927.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,194.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $957.35 | 2019-2025 | |
| Genzyme Corporation | $945.05 | 2019-2025 | |
| Ucb, INC. | $703.04 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $638.87 | 2019-2025 | Adbry, Spevigo |
| Regeneron Healthcare Solutions, INC. | $504.77 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $492.90 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $471.15 | 2019-2025 | Tremfya |
| Pfizer INC. | $457.14 | 2019-2025 | |
| Incyte Corporation | $337.88 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $325.86 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Sun Pharmaceutical Industries INC. | $321.77 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| Amgen INC. | $268.82 | 2019-2024 | Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $236.16 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $167.24 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $155.43 | 2019-2021 | |
| Dermavant Sciences, INC. | $116.61 | 2022-2024 | Vtama |
| Almirall LLC | $107.67 | 2019-2025 | Klisyri |
| Organon LLC | $94.06 | 2024-2025 | Vtama, Hadlima |
| Biofrontera INC. | $85.69 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $70.74 | 2019-2025 | |
| Dusa Pharmaceuticals, INC. | $52.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.30 | 2022-2024 | Spevigo |
| Botanix Sb INC | $30.85 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $28.15 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.29 | 2020-2024 | Jublia |
| Dermira, INC. | $22.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $17.26 | 2022 | |
| Medline Industries LP | $14.19 | 2019 | |
| Strata Skin Sciences, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Langer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.